GSK pledges £45m to Fleming Initiative to fight AMR
Betsy Goodfellow | May 16, 2024 | News story | Research and Development | AMR, Fleming Initiative, GSK, Microbiology, funding
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative and collaborative approach to tackle antimicrobial resistance (AMR).
The initiative is led by the Imperial College Healthcare NHS Trust and Imperial College London, UK, and intends to ‘bring together world-class scientific, technology, policy and behavioural science expertise with clinical experience in a global network of centres to find, test and scale solutions to AMR’, according to the company’s press release.
GSK’s £45m is intended to be used on approved projects which aim to utilise new technology, such as artificial intelligence (AI) to better understand and use complex scientific data, identify new treatment options, understand how surveillance approaches can improve detection of infections, and improve our understanding of how drug-resistant infections are transmitted, as well as how they can be prevented.
There will also be a strong focus on diagnostics, education and public engagement to reduce AMR, with a particular emphasis on countries most severely impacted by AMR where poverty, climate change and health inequality exacerbate the issues it can cause.
Emma Walmsley, chief executive officer of GSK, commented: “This will be an important collaboration for GSK building on our long- standing commitment to tackling AMR and our focus on disease prevention. The Fleming Initiative will bring together global resources and expertise from across different sectors to better understand the factors contributing to this growing threat and most importantly, drive action and solutions. We are proud to be a founding partner, and hope others will join us to support this urgent priority.”
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …
Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform
UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance …
